Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres(Mayo Clinic in Arizona), Ronald D. Perrone(Tufts Medical Center), Kaleab Z. Abebe(University of Pittsburgh), Franz T. Winklhofer(University of Kansas), Godela Brosnahan(University of Colorado Denver), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Frederic F. Rahbari-Oskoui(Emory University), Dana C. Miskulin(Tufts University), Michael F. Flessner, Theodore I. Steinman(Beth Israel Deaconess Medical Center), Marie C. Hogan(Mayo Clinic), William E. Braun(Cleveland Clinic), Charity G. Moore(University of Pittsburgh Medical Center), Robert W. Schrier(University of Denver), Jared J. Grantham(National Institutes of Health), Arlene B. Chapman(Emory University), Peter C. Harris(Mayo Clinic)
Cited by 290
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
|New England Journal of Medicine|2006|1.2k
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Temporal relationships between hormonal and hemodynamic changes in early human pregnancy
|Kidney International|1998|535